AbbVie Inc. (NYSE:ABBV)

Money close-up

Investors Were Not Impressed With AbbVie Q4 Earnings

AbbVie Inc. (NYSE: ABBV) reported its fourth-quarter financial results after the markets closed Thursday. The company said it had $1.13 in earnings per share (EPS) on $6.36 billion in revenue. ...
Read Full Story »
Pills and tablets

What to Look For in AbbVie Earnings

AbbVie Inc. (NYSE: ABBV) is scheduled to report its fourth-quarter financial results before the markets open Friday. The consensus estimates from Thomson Reuters are calling for $1.12 in earnings per ...
Read Full Story »
Medicine pills

Short Sellers Become More Selective on Major Pharma

The short interest data have been released for the January 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
buy now

4 Jefferies Growth Stocks to Buy as January Selling Presents Big Opportunity

Our 24/7 Wall St. research team did some digging, and we came up with a statistic you won’t find hard to believe. The current bearish sentiment numbers from American Association of ...
Read Full Story »
Medicine pills

Major Pharma Short Sellers Increase Bets

The short interest data have been released for the December 31 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Boeing 777-300er

Jefferies Dividend Franchise Picks Stocks to Buy on Sale After Big Market Sell-Off

After the first week of trading for 2016, many investors are feeling pretty queasy as we head into earnings season with the big banks leading off this week. With the ...
Read Full Story »
Medicine pills

Major Pharma Short Interest Takes Another Giant Leap Forward

The short interest data have been released for the December 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
2016 road ahead

Top-Yielding Jefferies Franchise List Stocks to Buy for 2016

With very little trading time left in what has been a disappointing 2015, many investors are trying to sort out the landscape for 2016. One thing is for sure, despite ...
Read Full Story »
Medicine pills

Short Interest in Major Pharma Takes a Giant Leap

The short interest data have been released for the November 30 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Medicine pills

Jefferies Top Pharma Stock Picks for 2016

Although most pharmaceutical stocks might trade down in the market Monday afternoon, most investors are looking past just the day and at what these stocks can do in the future. In ...
Read Full Story »
investing

Jefferies Makes Year-End Changes to Franchise List of Stocks to Buy

As we have reported recently, many of the top firms on Wall Street that we cover at 24/7 Wall St. have made some final tweaks and changes to their top ...
Read Full Story »
buy sell

Top Analyst Upgrades and Downgrades: AbbVie, CDW, CSC, Eli Lilly, Ericsson, Gold Fields, JD.com, Nokia, Rackspace and Many More

Stocks were indicated to open higher on Tuesday. Investors have bought stocks on pullbacks for four years now in a bull market that is nearing seven years old. 24/7 Wall ...
Read Full Story »
blue chip stocks

Jefferies Has 4 Blue Chip High-Dividend Franchise Picks to Buy Now

As we close in on the end of 2015, many of the top firms on Wall Street are fine-tuning the top picks list of stocks to buy that they present ...
Read Full Story »
Stock market tickers

9 Stocks to Avoid in December and Beyond

December has historically been a good month for the stock market, but there are plenty of individual stocks that don’t look like attractive bets as we near the end of ...
Read Full Story »
Medicine pills

Jefferies Reveals Top 5 Pharma Stock Picks for Growth and Dividends

After a pullback in the sector earlier in the third quarter, it seems that a rising tide has brought pharmaceuticals back to the forefront. As a result, one key analyst ...
Read Full Story »